Compare PepsiCo, Inc. (PEP) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Pfizer Inc — how do they compare? PepsiCo, Inc. trades at $126.5 (market cap $174.89B), while Pfizer Inc trades at $27.93 (market cap $158.56B). The key difference: PepsiCo, Inc. and Pfizer Inc are close in size by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and Pfizer Inc for 158 Days on average.
| PEP | PFE | |
|---|---|---|
Market Cap | $174.89B | $158.56B |
Volume | 23,968,864 | 44,138,282 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $29.02 |
52-Week Low | $123.64 | $23.67 |
Typical Hold Time | 107 Days | 158 Days |
Enterprise Value | $215.61B | $210.06B |
Dividend Yield | 4.61% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $123.64, down 1.65% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $2.34 exceeding expectations. Revenue growth remains steady at $93.93B for 2025, though net income margin declined to 8.77%. Recent news highlights price adjustments for snack products and sponsorship changes.
PepsiCo presents a mixed investment case with strong profitability metrics (ROE 51.59%) and analyst consensus price target of $146.77 (18.7% upside), but faces headwinds from consumer price sensitivity and technical weakness. The company's cash flow stability and dividend payments provide defensive characteristics, though execution risks in North American markets warrant monitoring.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
